http://www.nbrc.ac.in/faculty/ranjit/Giri-JNChem-Curcumin.pdf.pdf where they state
===
Me: There’s lots of literature on this. Some recommendations are to take 400 to 600 mg of extracts three times a day. Others, just add Turmeric to food or drink it as teas. Some recommend taking with vitamin ‘D’, say 2000 mg/day? but I have not investigated this link.
Some links on the web state a 30% reduction in plaques after a 30 day trial at the above dosages.
The spice is available at http://www.amazon.com/Indus-Organic-Turmeric-Curcumin-Freshly/dp/B001FVLLK6/ref=sr_1_2?ie=UTF8&qid=1373970581&sr=8-2&keywords=turmeric for a reasonable price.
===
Various References
References
1. van Duijn CM. Epidemiology of the dementia: recent developments and new approaches. J Neurol Neurosurg Psychiatry 1996;60:478–488. [Pubmed]
2. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB International workshop. Neurology 1996;47:1113–1124. [Pubmed]
3. Rasmusson DX, Brandt J, Steele C, et al. Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer’s disease neuropathology. Alzheimer Dis Assoc Disord 1996;10:180–188. [Pubmed]
4. Verghese J, Crystal HA, Dickson DW, et al. Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 1999;53:1974–1982. [Pubmed]
5. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology 2000;54:S4–S9. [Pubmed]
6. Farrer L. Intercontinental epidemiology of Alzheimer’s disease: a global approach to bad gene hunting. JAMA 2001;285:796–798. [Pubmed]
7. Skoog I. A population-based study of dementia in 85 year olds. N Engl J Med 1993;328:153–158. [Pubmed]
8. McKeith IG. Clinical Lewy body syndromes. Ann N Y Acad Sci 2000;920:1–8. [Pubmed]
9. Inkeda M, Hokoishi K, Maki N, et al. Increased prevalence of vascular dementia in Japan: a community-based epidemiological study. Neurology 2001;57:839–844. [Pubmed]
10. Hardy J. Molecular classification of Alzheimer’s disease. Lancet 1991;1:1342–1343.
11. Corey-Bloom J. The natural history of Alzheimer’s disease. In: O’Brien J, Ames D, Burns A, eds. Dementia. 2nd ed. London: Arnold, 2000:405–415.
12. Eastwood R, Reisberg B. Mood and behaviour. In: Panisset M, Stern Y, Gauthier S, eds. Clinical diagnosis and management of Alzheimer’s disease. 1st ed. London: Dunitz, 1996:175–189.
13. Mirea A, Cummings J. Neuropsychiatric aspects of dementia. In: O’Brien J, Ames D, Burns A, eds. Dementia. 2nd ed. London: Arnold, 2000:61–79.
14. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–1364. [Pubmed]
15. Folstein MF, Folstein SE, McHugh PR. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198. [Pubmed]
16. Burns A, Lawlor B, Craig S. Assessment scales in old age psychiatry. London: Martin Dunitz, 1998.
17. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer’s disease. Alzheimer Dis Assoc Disord 1997;11:S51–S56. [Pubmed]
18. Gelinas I, Gauthier L, McIntyre M, et al. Development of a functional measure for persons with Alzheimer’s disease: the Disability Assessment for Dementia. Am J Occup Ther 1999;53:471–481. [Pubmed]
19. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179–186. [Pubmed]
20. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2005. [Pubmed]
21. Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging 2008;3:211–225. [Pubmed]
22. Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer’s disease. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2008.
23. Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol 2009;8:39–47. [Pubmed]
24. Kavirajan H, Schneider LS, Kavirajan Harish, et al. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007;6:782–792. [Pubmed]
25. Roman GC, Salloway S, Black SE, et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 2010;41:1213–1221. [Pubmed]
26. Erkinjuntti T, Gauthier S, Bullock R, et al. Galantamine treatment in Alzheimer’s disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). J Psychopharmacol 2008;22:761–768. [Pubmed]
27. Ballard C, Sauter M, Scheltens P, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin 2008;24:2561–2574. [Pubmed]
28. National Institute for Health and Clinical Excellence. Dementia: supporting people with dementia and their carers in health and social care. November 2006. http://www.nice.org.uk/CG42 (last accessed 25 April 2012).
29. Feldman HH, Pirttila T, Dartiques JF, et al. Analyses of mortality risk in patients with dementia treated with galantamine. Acta Neurol Scand 2009;119:22–31. [Pubmed]
30. Birks J, Grimley Evans J, Lee H. Ginkgo biloba for cognitive impairment and dementia. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2007.
31. Weinmann S, Roll S, Schwarzbach C, et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 2010;10:14. [Pubmed]
32. Janssen IM, Sturtz S, Skipka G, et al. Ginkgo biloba in Alzheimer’s disease: a systematic review. Wien Med Wochenschr 2010;160:539–546. [Pubmed]
33. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2006. [Pubmed]
34. Doody RS, Tariot PN, Pfeiffer E, et al. Meta-analysis of six-month memantine trials in Alzheimer’s disease. Alzheimer Dement 2007;3:7–17. [Pubmed]
35. Mecocci P, Bladstrom A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer’s disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry 2009;24:532–538. [Pubmed]
36. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:969–977. [Pubmed]
37. Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trials. Drug Saf 2008;31:577–585. [Pubmed]
38. Woods B, Spector A, Jones C, et al. Reminiscence therapy for dementia. In: The Cochrane Library: Issue 2, 2011. Chichester: John Wiley & Sons, Ltd. Search date 2004.
39. Hulme C, Wright J, Crocker T, et al. Non-pharmacological approaches for dementia that informal carers might try or access: a systematic review. Int J Geriatr Psychiatry 2010;25:756–763. [Pubmed]
40. Olazaran J, Reisberg B, Clare L, et al. Nonpharmacological therapies in Alzheimer’s disease: a systematic review of efficacy. Dement Geriatr Cogn Disord 2010;30:161–178. [Pubmed]
41. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol 2009;5:140–152. [Pubmed]
42. Freund Levi Y, Eriksdotter Jönhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006;63:1402–1408. [Pubmed]
43. McGuinness B, O’Hare J, Craig D, et al. Statins for the treatment of dementia. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2008. [Pubmed]
44. Rands G, Orrel M, Spector A. Aspirin for vascular dementia. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2008.
45. Tabet N, Feldmand H. Ibuprofen for Alzheimer’s disease. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2002.
46. Tabet N, Feldman H. Indomethacin for Alzheimer’s disease. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2004.
47. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819–2826. [Pubmed]
48. Soininen H, West C, Robbins J, et al. Long-term efficacy and safety of celecoxib in Alzheimer’s disease. Dement Geriatr Cogn Disord 2007;23:8–21. [Pubmed]
49. Pasqualetti P, Bonomini C, Dal Forno G, et al. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease. Aging Clin Exp Res 2009;21:102–110. [Pubmed]
50. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer’s disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 2009;21:813–824. [Pubmed]
51. Auchus AP, Brashear HR, Salloway S. Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007;69:448–458. [Pubmed]
52. Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer’s disease. N Eng J Med 2007;357:1382–1392. [Pubmed]
53. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007;69:459–469. [Pubmed]
54. Gentile S. Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. Psychopharmacology 2010;212:119–129. [Pubmed]
55. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Eng J Med 2006;355:1525–1538. [Pubmed]
56. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009;8:151–157. [Pubmed]
57. Schneider LS, Dagerman KS, Insel PI. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomised placebo-controlled trials. JAMA 2005;294:1934–1943. [Pubmed]
58. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293:596–608. [Pubmed]
59. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Eng J Med 2005;353:2335–2341. [Pubmed]
60. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. In: The Cochrane Library: Issue 2, 2011. Chichester: John Wiley & Sons, Ltd. Search date 2010.
61. Maidment ID, Fox CG, Boustani M, et al. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother 2008;42:32–38. [Pubmed]
62. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008;23:537–545. [Pubmed]
63. Forbes D, Forbes S, Morgan DG, et al. Physical activity programs for persons with dementia. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2007.
64. Potter R, Ellard D, Rees K, et al. A systematic review of the effects of physical activity on physical functioning, quality of life and depression in older people with dementia. Int J Geriatr Psychiatry 2011;26:1000–1011. [Pubmed]
65. Burns A, Perry E, Holmes C, et al. A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer’s disease. Dement Geriatr Cogn Disord 2011;31:158–164. [Pubmed]
66. Rolland Y, Pillard F, Klapouszczak A, et al. Exercise program for nursing home residents with Alzheimer’s disease: a 1-year randomized, controlled trial. J Am Geriatr Soc 2007;55:158–165. [Pubmed]
67. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc 2011;59:577–585. [Pubmed]
68. Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry 2010;18:332–340. [Pubmed]
69. Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011;378:403–411. [Pubmed]
70. Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr 2008;20:293–308. [Pubmed]
pagecal 